Preclinical studies indicate that lenvatinib decreases the population of tumor- associated macrophages, increases CD8+ T cell infiltration, and augments the activity of PD-1 inhibitors; therefore, lenvatinib is a rational combination partner for pembrolizumab [3,4]. The gene discussed is RPL17; the disease is neoplasm.